5 Things a cardiologist needs to know about GLP-1RA First, prof. Montanya describes the US and European recommendations for the use of GLP-1RA in T2DM patients, and then discusses when to intitiate GLP-1RA in patients with high CV risk or clinical ASCVD, CKD, or HF, or in those with low CV risk.
5 Things a cardiologist needs to know about GLP-1RA Prof. Sattar describes the mechanism of action of GLP-1RAs and provides potential explanations for the cardiovascular benefit observed with these drugs.
The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.
AHA 2020 The nonsteroidal MRA finerenone, evaluated in the FIDELIO-DKD trial, reduced the risk on renal and CV outcome compared to placebo in CKD and T2DM patients with or without a history of CVD.
AHA 2020 The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.
AHA 2020 The primary CV endpoint was reduced by the dual SGLT1 and SGLT2 inhibitor sotagliflozin compared to placebo in patients with diabetes and CKD, and in patients with diabetes and ADHF.
5 Things a cardiologist needs to know about GLP-1RA Prof. Jacob discusses the shift in management of diabetes by a glycemic approach towards prevention of CV complications. He describes the evolution of the treatment recommendations in T2DM management.
AHA 2020 Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.
A prespecified subanalysis of ISAR-REACT 5 demonstrated that ticagrelor and prasugrel had comparable efficacy with regard to reducing ischemic events in patients with diabetes, with a similar risk for bleeding.
There are barriers to intensify treatment in T2DM patients leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.
In the FIDELIO-DKD trial, finerenone lowered the risk of CKD progression and CV events in patients with CKD and type 2 diabetes compared to placebo.
The AHA has published a scientific statement on evidence for the cardiorenal protective effects of SGLT2i and GLP-1RAs on outcomes in patients with CKD and T2DM.